Anti-EIF2AK2/PKR monoclonal antibody

The Alternative Names of target: EIF2AK2, PKR,Interferon-induced, double-stranded RNA-activated protein kinase,Eukaryotic translation initiation factor 2-alpha kinase 2 (eIF-2A protein kinase 2), Interferon-inducible RNA-dependent protein kinase, P1/eIF-2A protein kinase, Protein kinase RNA-activated (PKR, Protein kinase R), Tyrosine-protein kinase EIF2AK2, p68 kinase,PKR,PRKR,DYT33,LEUDEN,EIF2AK1,PPP1R83
Pre-made anti-EIF2AK2/PKR monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.

Target products collectionGo to EIF2AK2/PKR products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T51102-Ab-1/ GM-Tg-hg-T51102-Ab-2 Anti-Human EIF2AK2/PKR monoclonal antibody Human
GM-Tg-rg-T51102-Ab-1/ GM-Tg-rg-T51102-Ab-2 Anti-Rat EIF2AK2/PKR monoclonal antibody Rat
GM-Tg-mg-T51102-Ab-1/ GM-Tg-mg-T51102-Ab-2 Anti-Mouse EIF2AK2/PKR monoclonal antibody Mouse
GM-Tg-cynog-T51102-Ab-1/ GM-Tg-cynog-T51102-Ab-2 Anti-Cynomolgus/Rhesus macaque EIF2AK2/PKR monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-T51102-Ab-1/ GM-Tg-felg-T51102-Ab-2 Anti-Feline EIF2AK2/PKR monoclonal antibody Feline
GM-Tg-cang-T51102-Ab-1/ GM-Tg-cang-T51102-Ab-2 Anti-Canine EIF2AK2/PKR monoclonal antibody Canine
GM-Tg-bovg-T51102-Ab-1/ GM-Tg-bovg-T51102-Ab-2 Anti-Bovine EIF2AK2/PKR monoclonal antibody Bovine
GM-Tg-equg-T51102-Ab-1/ GM-Tg-equg-T51102-Ab-2 Anti-Equine EIF2AK2/PKR monoclonal antibody Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T51102-Ab-1/ GM-Tg-hg-T51102-Ab-2; GM-Tg-rg-T51102-Ab-1/ GM-Tg-rg-T51102-Ab-2;
GM-Tg-mg-T51102-Ab-1/ GM-Tg-mg-T51102-Ab-2; GM-Tg-cynog-T51102-Ab-1/ GM-Tg-cynog-T51102-Ab-2;
GM-Tg-felg-T51102-Ab-1/ GM-Tg-felg-T51102-Ab-2; GM-Tg-cang-T51102-Ab-1/ GM-Tg-cang-T51102-Ab-2;
GM-Tg-bovg-T51102-Ab-1/ GM-Tg-bovg-T51102-Ab-2; GM-Tg-equg-T51102-Ab-1/ GM-Tg-equg-T51102-Ab-2
Products Name Anti-EIF2AK2/PKR monoclonal antibody
Format mab
Target Name EIF2AK2/PKR
Protein Sub-location Introcelluar Protein
Category of antibody
Derivation (species) Mouse
CH1+2+3 Isotype
(Receptor identification) 		IgG
Type of Light Chain (VD-LC) N/A
Expression platform Mammalian Expression
Bioactivity validation Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
Tag Fc
Products description Pre-made anti-EIF2AK2/PKR monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.